Biokey
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A diagnostics developer utilizing advanced NGS and PCR technologies for infectious disease and genetic testing.
Infectious DiseaseGenetics & Genomics
Technology Platform
A dual-technology platform combining targeted next-generation sequencing (NGS) for comprehensive profiling and digital PCR (dPCR) for ultra-sensitive quantification.
Opportunities
Growing adoption of NGS in clinical practice for oncology and prenatal testing in China's expanding healthcare market.
Risk Factors
Slower-than-expected reimbursement for NGS-based tests and rapid technological obsolescence in the sequencing field.
Competitive Landscape
Competes in the advanced diagnostics niche against other NGS-focused companies, requiring continuous innovation to maintain technical leadership.